Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576925 | 0.94 | MAPT (0.47) | MAPTL3MBTL1GAAPOLBALDH1A1 | |
| SCHEMBL2427540 | 0.86 | MAPT (0.56) | MAPTL3MBTL1GAAPOLBALDH1A1 | |
| SCHEMBL27053828 | 0.85 | HPGD (0.49) | MAPTL3MBTL1GAAALDH1A1VNN1 | |
| SCHEMBL23043726 | 0.84 | KDM4E (0.49) | GAAPOLBVNN1KMT2ARAB9A | |
| SCHEMBL31048202 | 0.84 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL5089657 | 0.83 | CA12 (0.47) | L3MBTL1ALDH1A1VNN1TSHRKMT2A | |
| SCHEMBL6025472 | 0.83 | ALDH1A1 (0.56) | MAPTL3MBTL1POLBALDH1A1TSHR | |
| SCHEMBL13092558 | 0.82 | GAA (0.50) | MAPTL3MBTL1GAAPOLBALDH1A1 | |
| SCHEMBL20583636 | 0.81 | LMNA (0.50) | MAPTL3MBTL1GAAALDH1A1TSHR | |
| SCHEMBL31552196 | 0.80 | RIPK1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | disclosed |
| EP-4476221-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | Bayer Aktiengesellschaft (DE) | 2024-12-18 | — | — | EP | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2023152255-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023152255-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | MAPT 4220/4885L3MBTL1 2216/4885GAA 2436/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | MAPT 3825/4885L3MBTL1 3503/4885GAA 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.